-
公开(公告)号：US07928094B2
公开(公告)日：2011-04-19
申请号：US11981861
申请日：2007-10-31
IPC分类号： A61K31/33 , A61K31/195 , A61K31/13
CPC分类号： A61K31/132 , A61K31/15
摘要： Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.
摘要翻译： 用于治疗患有疾病，病症和病症（包括糖尿病）的患者的新方法，包括施用例如铜结合化合物。
-
公开(公告)号：US07459446B2
公开(公告)日：2008-12-02
申请号：US11023827
申请日：2004-12-28
IPC分类号： A61K31/33 , A61K31/415 , A61K31/195 , A61K31/13
CPC分类号： A61K31/132 , A61K31/15
摘要： Novel methods of treating a patient for diseases, disorders, and conditions including diabetes mellitus, comprising administering, for example, copper binding compounds.
摘要翻译： 用于治疗患有疾病，病症和病症（包括糖尿病）的患者的新方法，包括施用例如铜结合化合物。
-
公开(公告)号：US06897243B2
公开(公告)日：2005-05-24
申请号：US10226685
申请日：2002-08-23
CPC分类号： A61K31/132 , A61K31/15
摘要： The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.
摘要翻译： 本发明涉及通过向所述个体施用有效量的铜螯合剂，肼化合物和/或底物类似物来治疗患有糖尿病的个体的方法。 本发明还涉及通过减少所述个体中的果糖胺奥曲肽酶活性来治疗患有糖尿病的个体的方法。 其中提供了关于治疗，药物组合物，剂量范围以及果糖胺氧化酶抑制剂用于降低果糖胺氧化酶活性的公开。
-
公开(公告)号：US06610693B2
公开(公告)日：2003-08-26
申请号：US09975751
申请日：2001-10-10
申请人： John Richard Baker
发明人： John Richard Baker
IPC分类号： A61K31495
CPC分类号： A61K31/132 , A61K31/15
摘要： The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening fructosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of fructosamine oxidase enzyme inhibitors to lessen fructosamine oxidase activity.
-
公开(公告)号：US20150164826A1
公开(公告)日：2015-06-18
申请号：US14573211
申请日：2014-12-17
IPC分类号： A61K31/131 , A61K31/194
CPC分类号： A61K31/132 , A61K9/0019 , A61K31/131 , A61K31/194 , A61K31/30
摘要： This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.
摘要翻译： 本发明部分地涉及这样的剂量和剂量制剂的新剂量，剂量制剂和给药途径，所述剂量和剂量制剂含有一种或多种铜螯合剂，例如一种或多种三胺活性剂，包括三嗪类似物， 三碘胺盐，三氮烯前药和三异胺衍生物，可用于治疗疾病，病症和病症，包括铜可能发挥作用的适应症。
-
公开(公告)号：US06348465B1
公开(公告)日：2002-02-19
申请号：US09671967
申请日：2000-09-27
申请人： John Richard Baker
发明人： John Richard Baker
IPC分类号： A61K31495
CPC分类号： A61K31/132 , A61K31/15
摘要： The present invention relates to methods of treating an individual with diabetes mellitus by administering to said individual an effective amount of copper chelators, hydrazine compounds, and/or substrate analogues. The invention also relates to methods of treating an individual with diabetes mellitus by lessening frictosamine odixase activity in said individual. Provided within is disclosure pertaining to treatment, pharmaceutical compositions, dosage ranges, and uses of frictosaminc oxidase enzyme inhibitors to lessen fructosamine oxidase activity.
摘要翻译： 本发明涉及通过向所述个体施用有效量的铜螯合剂，肼化合物和/或底物类似物来治疗患有糖尿病的个体的方法。 本发明还涉及通过减少所述个体中的氟沙胺奥曲肽酶活性来治疗患有糖尿病的个体的方法。 提供关于治疗，药物组合物，剂量范围以及氟虫胺氧化酶抑制剂用于降低果糖胺氧化酶活性的公开内容。
-
公开(公告)号：US20160324804A1
公开(公告)日：2016-11-10
申请号：US15096570
申请日：2016-07-22
IPC分类号： A61K31/132 , A61K9/00
CPC分类号： A61K31/132 , A61K9/0019 , A61K31/131 , A61K31/194 , A61K31/30
摘要： This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.
-
公开(公告)号：US06855511B2
公开(公告)日：2005-02-15
申请号：US09818344
申请日：2001-03-26
申请人： John Richard Baker
发明人： John Richard Baker
摘要： Methods whereby, by reference to fructosamine oxidase activity in blood plasma of a patient or patients, the risk of diabetes associated vascular complications can be assessed, candidate fructosamine oxidase inhibitors and/or antagonists can be identified or tested and the inhibition and/or antagonism of the fructosamine oxidase inhibition and/or antagonism of a patient can be assessed.
摘要翻译： 通过参考患者或患者血浆中的果糖胺氧化酶活性的方法，可以评估糖尿病相关的血管并发症的风险，候选果糖胺氧化酶抑制剂和/或拮抗剂可被鉴定或测试，并且抑制和/或拮抗 可以评估患者的果糖胺氧化酶抑制和/或拮抗作用。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
